CD4/CD8 Ratio of Pleural Effusion Is A Prognostic Predictor for Non-Small Cell Lung Cancer Patients Under Immune Checkpoint Inhibitor Treatments

Po-Hsin Lee  
Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

Tsung-Ying Yang  
Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

Kun-Chieh Chen  
Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan

Yen-Hsiang Huang  
Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

Jeng-Sen Tseng  
Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

Kuo-Hsuan Hsu  
Division of Critical Care and Respiratory Therapy, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

Yu-Chen Wu  
National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan

Ko-Jiunn Liu  
National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan

Gee-Chen Chang  
Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan

Research Article

Keywords: ICIs, CD4/CD8, effusion, cancer

DOI: https://doi.org/10.21203/rs.3.rs-145181/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Pleural effusion is a rare immune-related adverse event for lung cancer patients receiving immune checkpoint inhibitors (ICIs). We enrolled 281 lung cancer patients treated with ICIs and 17 were analyzed. We categorized the formation of pleural effusion into 3 patterns: type 1, rapid and massive; type 2, slow and indolent and type 3, with disease progression. CD4/CD8 ratio of 1.93 was selected as the cutoff threshold to predict survival. Most patients of types 1 and 2 effusions possessed pleural effusion with CD4/CD8 ratios \( \geq 1.93 \). The median OS time in type 1, 2, and 3 patients were not reached, 24.8, and 2.6 months. The median PFS time in type 1, 2, and 3 patients were 35.5, 30.2, and 1.4 months. The median OS for the group with pleural effusion CD4/CD8 \( \geq 1.93 \) and \( < 1.93 \) were not reached and 2.6 months. The median PFS of those with pleural effusion CD4/CD8 \( > 1.93 \) and \( < 1.93 \) were 18.4 and 12.2 months. In conclusion, patients with type 1 and 2 effusion patterns had better survival than those with type 3. Type 1 might be interpreted as pseudoprogression of malignant pleural effusion. CD4/CD8 ratio \( \geq 1.93 \) in pleural effusion is a good predicting factor for PFS.

Introduction

Immune checkpoint inhibitors (ICIs) have become promising agents against a variety of cancers. However, in some patients, concomitant immune-related adverse events (irAEs) develop. Among organs affected by immune checkpoint blockade, pleural involvement is rare. Under ICI treatment, pseudoprogression may develop, with a transient increase in the tumor size before regression\(^1\). Pseudoprogression in lung-cancer patients occurs not only in the solid part of the tumor, but also has been reported in malignant spread to pleural and pericardial space with the presentation of rapidly accumulating recurrent effusions\(^2\). The clinical course and outcomes of patients receiving ICIs followed by pleural effusion development are poorly known.

IrAEs involving different organs may result from various mechanisms\(^3\). For example, in myocarditis, the inflammatory infiltration of T cells is predominantly CD8\(^4\), whereas in pericardial involvement, T cell infiltration is predominantly CD4\(^5\). Which types of lymphocytes are involved in pleural effusion under ICIs remained unknown.

In the present study, we aimed to categorize the clinical presentations of ICI-related pleural effusion and analyze the lymphocyte components in the pleural effusion in relation to the clinical outcomes of non-small cell lung cancer (NSCLC) patients receiving ICIs.

Methods

Study design

NSCLC patients were enrolled retrospectively at Taichung Veterans General Hospital from Oct 2015 to Dec 2019, during which ICI treatments were initiated. The last follow-up was on May 31, 2020. Eligible patients all had non-infectious pleural effusion after ICI use. The exclusion criteria were as follows: no cytology results of pleural effusion, mortality of unknown etiology, specimens for lymphocyte analysis not from pleural effusion, the duration from last dose of ICI to development of pleural effusion exceeded 12 months. Patients receiving ICIs and docetaxel were excluded, since docetaxel was known to cause pleural effusion\(^6\). This study was approved by the Institutional Review Board of Taichung Veterans General Hospital (IRB No. CF16018A). Written informed consents for clinical data records, genetic and immunological testing were obtained from all patients. All methods were carried out in accordance with the relevant approved guidelines and regulations.

Definition of disease progression and development of pleural effusion

We categorized the pattern of pleural effusion formation of our patients into three types: (1) Type 1: rapid production, without disease progression, within one month after ICIs use, (2) Type 2: slow production, without disease progression, one month after ICIs use, (3) Type 3: pleural effusion due to disease progression even with ICI treatments. Disease progression was defined as follows: (1) newly developed malignant pleural effusion which did not turn from positive to negative from serial cytology exams, (2) pleural effusion negative for malignancy but with disease progression at other locations.

We defined newly developed pleural effusion as follows: (1) no pleural effusion before ICI use, but effusion developed after treatments, (2) pleural effusion existed before ICI use and rate of effusion accelerated after treatments. The definition of acceleration was as follows: (1) a pigtail catheter was inserted for symptomatic relief of pleural effusion, or (2) the frequency of thoracentesis increased.

Pleural effusion analysis and lymphocyte subset measurement

We analyzed lymphocyte subsets in pleural effusion which was collected the first time patients had received thoracentesis after ICI use. Since no less than 150 ml of pleural effusion was required for analysis, the insufficient pleural effusions of some patients were not analyzed at the first time.

Mononuclear cells in the pleural effusion were collected through density gradient centrifugation with Ficoll-Paque. For cell type analyses based on surface molecules, cells were first stained with different fluorescence-labeled monoclonal antibodies and then analyzed with flow cytometry. Cells were gated based on forward scatter channel and side scatter channel to select lymphocytes. For T cell subset study, cells were stained with phycoerythrin (PE)-anti-CD3, PerCP-anti-CD4, and FITC-anti-CD8, and cells expressing CD3 were gated for CD4 and CD8 analyses. For B cell study, cells were stained with FITC-anti-CD3 and PE-anti-CD19, and the percentage of CD3-CD19 + cells was determined. Isotype-matched control monoclonal antibodies were obtained from BD PharMingen and BioLenged. Details of equipment and antibody are shown in online supplemental table 1.

Analyses of Cytokine productions in pleural effusion

Pleural effusion was first centrifuged to remove cells and debris. We then used the sandwich-enzyme-linked immunosorbent assay (ELISA) with the OptEIA kit (BD Pharmingen) to detect levels of IL-1, IL-2, IL-10, IL-12p70 and IFN-γ in the pleural effusion. We also used the DuoSet ELISA kit (R&D Systems Inc.,
Minneapolis, MN) to detect levels of IL-8 and IL-17. IL-6 and TNF-α levels were detected by ELISA (Invitrogen, Thermo Fisher Scientific, Waltham MA). Detection ranges with ELISA are shown in online supplemental table 2.

Identification of driver mutations and PD-L1 assay

Tumor specimens were procured for oncogenic mutation analyses as previously reported7. Five oncogenic drivers, including EGFR, KRAS, BRAF, HER2 and EML4-ALK, were tested. For patients with squamous cell carcinoma, oncogenic mutation analyses were not routinely performed.

Three commercial Programmed Death-ligand 1 (PD-L1) IHC assays, 22C3, SP142, and SP263, were performed for all patients when adequate specimens were available. The PD-L1 IHC 22C3 pharmDx was conducted on the DAKO Autostainer Link 48, while the Ventana PD-L1 SP142 and SP263 assays were conducted on the Ventana BenchMark platform.

Data records and response evaluation

Clinical data of individual patients included age, gender, Eastern Cooperative Oncology Group Performance Status (ECOG PS), tumor stage, smoking status, and thyroid function. The age, ECOG PS, and tumor stage were evaluated while ICIs were initiated. The overall survival (OS) and progression free survival (PFS) were analyzed from the beginning of ICI treatment. TNM (tumor, node, and metastases) staging was performed according to the 8th edition of the American Joint Committee for Cancer (AJCC) staging system. We adopted here unidimensional measurements as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Statistical methods

Fisher's exact test and Mann-Whitney U test were used to compare inter-group differences for categorical and continuous variables as appropriate. Univariate and multivariate Cox proportional hazard regression models were used to estimate the hazard ratio. The OS and PFS were estimated using the Kaplan-Meier method, whereas the between-group differences were assessed using the stratified log-rank test. Two-tailed tests with p values < 0.05 were considered statistically significant.

All analyses were performed with the IBM SPSS Statistics package, version 23 (IBM Corporation, Armonk, NY).

Results

Patient characteristics

We included a total 281 advanced (stage IIIb/IV) NSCLC patients with ICIs initiated. Among these patients, 168 patients were treated with pembrolizumab, 43 with nivolumab, 47 with atezolizumab, and 23 with durvalumab. Among them, 27 developed pleural effusion after ICI use, with 10 excluded. Among the remaining 17 patients, three were categorized as type 1, 5 as type 2, and 9 as type 3 (Fig. 1).

Their descriptive characteristics are summarized in Table 1. All the patients had reached advanced stages of lung cancer before ICI use. Adenocarcinoma was diagnosed in 13 patients, and three of them harboring EGFR mutations. Negative PD-L1 expression was found in 6 patients, low PD-L1 expression in 4 patients, and high PD-L1 expression in 5 patients. Of the 17 patients, 13 received lymphocyte subset analyses of their pleural effusions within one month after first thoracentesis.
## Table 1
Demographic data and characteristics of different pleural effusion types

|                                | All (N = 17) | Type 1 + Type 2 (N = 8) | Type 3 (N = 9) | P Value $^a$ |
|--------------------------------|--------------|-------------------------|---------------|-------------|
| **Age, medium (IQR)**          | 60.1 (52.6 ~ 65.8) | 63.0 (52.4 ~ 68.6) | 58.9 (53.9 ~ 61.6) | 0.423 |
| **Gender, N (%)**              |              |                         |               | 0.335       |
| Male                           | 10 (58.8)    | 6 (75)                  | 4 (44.4)      |             |
| Female                         | 7 (41.2)     | 2 (25)                  | 5 (55.6)      |             |
| **Smoking status, N (%)**      |              |                         |               | 0.347       |
| Ever smoker                    | 8 (47.1)     | 5 (62.5)                | 3 (33.3)      |             |
| Never smoker                   | 9 (52.9)     | 3 (37.5)                | 6 (66.7)      |             |
| **Stage, N (%)**               |              |                         |               | 1.000       |
| III B ~ IIC                    | 2 (11.8)     | 1 (12.5)                | 1 (11.1)      |             |
| IVA ~ IVB                      | 15 (88.2)    | 7 (87.5)                | 8 (88.9)      |             |
| **Brain metastasis before ICI, N (%)** |          |                         |               | 0.620       |
| Yes                            | 5 (29.4)     | 3 (37.5)                | 2 (22.2)      |             |
| No                             | 12 (70.6)    | 5 (62.5)                | 7 (77.8)      |             |
| **ECOG PS, N (%)**             |              |                         |               | 0.206       |
| 0 ~ 2                          | 14 (82.4)    | 8 (100)                 | 6 (66.7)      |             |
| 3 ~ 4                          | 3 (17.6)     | 0 (0)                   | 3 (33.3)      |             |
| **Pathology and driver mutation, N (%)** |          |                         |               | 1.000       |
| ADC without driver mutation    | 10 (58.8)    | 5 (62.5)                | 5 (55.6)      |             |
| ADC with EGFR mutation         | 3 (17.6)     | 1 (12.5)                | 2 (22.2)      |             |
| Non-ADC NSCLC                  | 4 (23.5)     | 2 (25)                  | 2 (22.2)      |             |
| **PD-L1, N (%)**               |              |                         |               | 0.147       |
| <1%                            | 6 (35.3)     | 1 (12.5)                | 5 (55.6)      |             |
| 1~49%                          | 4 (23.5)     | 2 (25)                  | 2 (22.2)      |             |
| >=50%                          | 5 (29.4)     | 4 (50)                  | 1 (11.1)      |             |
| N/A                            | 2 (11.8)     | 1 (12.5)                | 1 (11.1)      |             |
| **ICI type, N (%)**            |              |                         |               | 0.689       |
| Pembrolizumab                  | 10 (58.8)    | 4 (50)                  | 6 (66.7)      |             |
| Nivolumab                      | 1 (5.9)      | 1 (12.5)                | 0 (0)         |             |
| Atezolizumab                   | 1 (5.9)      | 0 (0)                   | 1 (11.1)      |             |
| Durvalumab                     | 5 (29.4)     | 3 (37.5)                | 2 (22.2)      |             |
| **Hypothyroidism after ICI use, N (%)** |          |                         |               | 0.315       |
| Yes                            | 6 (35.3)     | 2 (25)                  | 4 (44.4)      |             |
| No                             | 9 (52.9)     | 6 (75)                  | 3 (33.3)      |             |
| N/A                            | 2 (11.8)     | 2 (22.2)                |               |             |
| **Pericardial effusion requiring drainage after ICI, N (%)** |          |                         |               | 0.576       |
| Yes                            | 3 (17.6)     | 2 (25)                  | 1 (11.1)      |             |
| No                             | 14 (82.4)    | 6 (75)                  | 8 (88.9)      |             |

ICI, immune checkpoint inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance status; ADC, adenocarcinoma; NSCLC, non-small cell lung cancer; N/A, not applicable; PR, partial response; SD, stable disease; PD, disease progression
All (N = 17) | Type 1 + Type 2 (N = 8) | Type 3 (N = 9) | p Value
--- | --- | --- | ---
Interval from ICI to 1st thoracentesis, months, medium (IQR) | 0.63 (0.30 ~ 4.87) | 1.9 (0.3 ~ 6.9) | 0.6 (0.3 ~ 1.9) | 0.815
Interval from 1st thoracentesis to CD4/CD8 ratio, months, medium (IQR) | 0 (0 ~ 0.97) | 0.9 (0 ~ 2.7) | 0 (0 ~ 0) | 0.093
CD4/CD8 ratio, N (%) | | | 0.036
>= 1.93 | 10 (58.8) | 7 (87.5) | 3 (33.3) |
< 1.93 | 7 (41.2) | 1 (12.5) | 6 (66.7) |
B cell ratio, N (%) | | | 0.131
>= 6.09 | 5 (29.4) | 4 (50) | 1 (11.1) |
< 6.09 | 12 (70.6) | 4 (50) | 8 (88.9) |
a) Probability value by Mann-Whitney U test and Fisher’s exact test.

ICI, immune checkpoint inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance status; ADC, adenocarcinoma; NSCLC, non-small cell lung cancer; N/A, not applicable; PR, partial response; SD, stable disease; PD, disease progression

Different types of pleural effusion

Clinical data and outcomes of the enrolled patients are shown in Table 2. The disease course and treatment timeline for patients of types 1 and 2 are shown in Fig. 2. Type 1 patients within 2 weeks after ICI use developed pleural effusion with or without pericardial effusion (one patient also received pericardial drainage), and pigtail catheters were applied to two patients. All these patients presented with pleural effusion before ICI use and one of them was found to have malignant pleural effusion. Malignant cells were found in pleural effusion after the initial treatment, but were then absent in the following serial thoracentesis. Type 2 patients developed pleural effusion one month after ICI use. Malignant pleural effusion was not documented before or after ICI use. Among type 3 patients, malignant pleural effusion persisted in 6 patients while disease progression to other organs was found in three patients.
Higher IL-8 levels in patients with pleural effusion CD4/CD8 ratio < 1.93

Of the 17 patients, 5 had elevated B cell ratios in their initial pleural effusion analyses, and 4 of them were with type 1 and type 2 effusions.

CD20+ B lymphocytes account for 5.81% of all leukocytes in malignant pleural effusion. Higher percentages of B cells were found in pleural effusions of patients without disease progression, especially in type 1 patients (Table 1). The optimal cutoff threshold was set at 1.93 in predicting OS, PFS, and the type of pleural effusion. The median OS in CD4/CD8 ≥ 1.93 group was not reached, whereas the median OS in CD4/CD8 < 1.93 was 2.7 months (Fig. 3B). The median PFS periods for patients with type 1, 2, and 3 effusion were 35.5, 30.2, and 1.4 months, respectively (Fig. 3B).

Pleural effusion with CD4/CD8 ratio ≥ 1.93 is a good predictor for survival

In univariate and multivariate analyses for OS or PFS before ICI use, Cox-regression showed no significantly related risk factor, like age, gender, smoking history, PD-L1 status, and brain metastasis (Table 3A and 3B). ECOG PS was identified as significant predictors associated with OS in both univariate and multivariate analyses similarly. ECOG PS and CD4/CD8 ratio were predictors of PFS. The median OS in CD4/CD8 ≥ 1.93 group was not reached, whereas the median OS in CD4/CD8 < 1.93 was 2.7 months (Fig. 3A). The median PFS of patients with CD4/CD8 > 1.93 was 18.2 months, and with this ratio < 1.93 was 1.2 months (Fig. 3C).

Elevated pleural effusion B cell percentages in type 1 patients

Higher percentages of B cells were found in pleural effusions of patients without disease progression, especially in type 1 patients (Table 2). The optimal cutoff percentage of B cells was 6.09% in predicting OS, PFS, and pleural effusion types (online supplemental Fig. 3). In a previous study, Nieto et al. reported CD20 + B lymphocytes account for 5.81% of all leukocytes in malignant pleural effusion so our finding of 6.09% is reasonable for defining “elevated” B cell ratio. Of the 17 patients, 5 had elevated B cell ratios in their initial pleural effusion analyses, and 4 of them were with type 1 and type 2 effusions.

Higher IL-8 levels in patients with pleural effusion CD4/CD8 ratio < 1.93

| No. | Age  | Gender | Smoking | PS | Cell type/Stage | Brain mets | PD-L1 | ICI | Cycle | PFS (m) | OS (m) | ICI to PE(m) | PE to CD4/CD8 (m) | Initial CD4/CD8 | Initial B cell ratio |
|-----|------|--------|---------|----|----------------|-----------|-------|-----|-------|--------|--------|--------------|-------------------|----------------|-------------------|
| 1   | 60.1 | M      | E       | 2  | ADC IVB        | No        | negative | n   | 92§   | 35.5   | 50.5#  | 0.2          | 1.7               | 1.89             | 0.3               |
| 2   | 79.0 | F      | N       | 2  | ADC IVA        | No        | high(+)  | P 8 | 56.6* | 56.6#  | 0.3     | 0.0          | 4.01              | 23.7             |
| 3   | 65.8 | M      | E       | 1  | ADC IVA        | No        | low(+)   | D 4 | 7.8#  | 7.8#   | 0.3     | 0.1          | 7.22              | 12.6             |
| 4   | 47.6 | F      | N       | 1  | IMA IIIC       | No        | N/A      | D 15 | 14.5# | 14.5#  | 7.9     | 4.5          | 3.84              | 0.3              |
| 5   | 74.3 | M      | N       | 1  | ADC®1 IVB      | Yes       | high(+)  | P 14§ | 13.3* | 13.3*  | 6.5     | 2.3          | 2.83              | 3.4              |
| 6   | 66.6 | M      | E       | 2  | SqCC IVB       | Yes       | high(+)  | P 1  | 6.6*  | 6.6*   | 0.3     | 0.0          | 6.22              | 2.7              |
| 7   | 51.9 | M      | E       | 1  | ADC IVA        | No        | high(+)  | D 26 | 14.0  | 14.0#  | 3.5     | 5.9          | 2.10              | 7.3              |
| 8   | 52.6 | M      | E       | 1  | ADC IVA        | Yes       | low(+)   | P 26§ | 30.2  | 31.3#  | 25.0    | 0.0          | 1.95              | 16.3             |
| 9   | 61.6 | F      | N       | 1  | ADC IVA        | No        | low(+)   | P 1  | 0.5   | 0.6    | 0.2     | 0.0          | 1.07              | 2.7              |
| 10  | 56.4 | M      | E       | 3  | ADC IVA        | No        | negative | P 1  | 0.9   | 2.2     | 0.3     | 0.0          | 1.85              | 1.6              |
| 11  | 64.4 | M      | N       | 2  | SqCC IVB       | No        | negative | A 2 | 1.6   | 2.3     | 0.6     | 1.0          | 13.23             | 1.5              |
| 12  | 60.3 | F      | N       | 4  | ADC®2 IVB      | No        | high(+)  | P 5  | 3.2   | 4.7     | 0.2     | 0.0          | 4.78              | 4.9              |
| 13  | 45.7 | F      | N       | 1  | ADC IVA        | No        | negative | P 6  | 5.0   | 29.9#  | 4.9     | 0.0          | 1.36              | 0.8              |
| 14  | 47.6 | M      | N       | 1  | ADC IVA        | Yes       | negative | P 2  | 1.2   | 2.6     | 0.7     | 0.7          | 1.90              | 3.8              |
| 15  | 58.9 | M      | N       | 3  | ADC®1 IVB      | Yes       | N/A      | P 1  | 0.8   | 0.8     | 0.6     | 0.0          | 1.90              | 2.5              |
| 16  | 68.1 | F      | E       | 1  | SqCC IIIIB     | No        | low(+)   | D 6  | 1.4   | 14.0    | 1.9     | 0.0          | 1.90              | 4.5              |
| 17  | 53.9 | F      | E       | 1  | SqCC IIIIB     | No        | low(+)   | D 39§ | 18.4  | 20.9#  | 19.1    | 0.0          | 8.50              | 34.0             |

ICI, immune checkpoint inhibitor; M, male; F, female; E, ever smoker; N, never smoker; PS, Eastern Cooperative Oncology Group performance status; ADC, adenocarcinoma; EGFR L858R mutation; SqCC, squamous cell carcinoma; @2, EGFR G719S mutation; Brain mets, brain metastasis before ICI use; n, nivolumab; P pembrolizum; *, no disease progression; #, survive; ICI to PE, time from ICI use to 1st thoracentesis; PE, pleural effusion; PE to CD4/CD8, interval from 1st thoracentesis before ICI, pleural effusion noted by image before ICI use; cytology (+), positive for malignant cell; cytology (-), negative for malignant cell; N/A, not applicable.

Table 2: Clinical data and outcomes of lung cancer patients developing pleural effusion after ICI use

Characteristics were compared between non-disease progression type (types 1 and 2) and disease progression type (type 3) (Table 1). In the non-disease progression group, 87.5% showed pleural effusion CD4/CD8 ratio ≥ 1.93, compared with 33.3% in the disease progression group (p = 0.036). The median OS in type 1 patients was not reached, whereas in type 2 was 24.8 months, and in type 3 was 2.6 months (Fig. 3B). The median PFS periods for patients with type 1, 2, and 3 effusion were 35.5, 30.2, and 1.4 months, respectively (Fig. 3D).
Expression levels of cytokines in pleural effusion were shown in online supplemental Fig. 4. IL-8 levels in pleural effusion of patients with CD4/CD8 ratios < 1.93 were higher than those with ratio ≥ 1.93 (online supplemental table 3A). Expression levels of cytokines were however similar across effusion types (online supplemental table 3B).

Table 3. Univariate and multivariate analyses of (A) Overall survival (OS) and (B) Progression free survival (PFS)

(A) Overall survival

| Variable                        | Univariate HR (95% CI) | p Value | Multivariate HR (95% CI) | p Value |
|---------------------------------|------------------------|---------|--------------------------|---------|
| Age                             | 1.00 (0.93-1.07)       | 0.866   |                          |         |
| Male gender                     | 1.38 (0.32-5.85)       | 0.666   |                          |         |
| Never smoker                    | 2.00 (0.48-8.43)       | 0.344   |                          |         |
| ECOG PS                         |                        |         |                          |         |
| 0-2                             | 1                      |         |                          |         |
| 3-4                             | 7.81 (1.52-40.29)      | 0.014   | 8.82 (1.48-52.66)        | 0.017   |
| Brain mets before ICI           | 0.97 (0.19-4.89)       | 0.973   |                          |         |
| PD-L1                           |                        |         |                          |         |
| <1%                             | 2.01 (0.36-11.11)      | 0.213   |                          |         |
| 1-49%                           | 0.77 (0.07-8.50)       | 0.829   |                          |         |
| >= 50%                          | 1                      |         |                          |         |
| CD4/CD8 ratio                   |                        |         |                          |         |
| <1.93                           | 1                      |         |                          |         |
| >=1.93                          | 0.31 (0.07-1.30)       | 0.108   | 0.285 (0.06-1.33)        | 0.111   |

(B) Progression free survival

| Variable                        | Univariate HR (95% CI) | p Value | Multivariate HR (95% CI) | p Value |
|---------------------------------|------------------------|---------|--------------------------|---------|
| Age                             | 0.95 (0.89-1.02)       | 0.158   |                          |         |
| Male gender                     | 1.07 (0.34-3.37)       | 0.915   |                          |         |
| Never smoker                    | 1.31 (0.41-4.12)       | 0.650   |                          |         |
| ECOG PS                         |                        |         |                          |         |
| 0-2                             | 1                      |         |                          |         |
| 3-4                             | 6.00 (1.30-27.72)      | 0.022   | 6.78 (1.29-35.49)        | 0.024   |
| Brain mets before ICI           | 1.02 (0.27-3.86)       | 0.980   |                          |         |
| PD-L1                           |                        |         |                          |         |
| <1%                             | 3.84 (0.77-19.33)      | 0.103   |                          |         |
| 1-49%                           | 2.10 (0.34-12.91)      | 0.424   |                          |         |
| >= 50%                          | 1                      |         |                          |         |
| CD4/CD8 ratio                   |                        |         |                          |         |
| <1.93                           | 1                      |         |                          |         |
| >=1.93                          | 0.27 (0.08-0.87)       | 0.028   | 0.25 (0.07-0.86)         | 0.027   |

a) Probability value by Cox regression model. ECOG PS, Eastern Cooperative Oncology Group performance status; mets, metastasis; ICI, immune checkpoint inhibitor; HR, hazard ratio; CI, confidence interval

Discussion
We have here found different presentations of lung cancer patients developing pleural effusion after receiving ICI. Three effusion developmental patterns were identified. Type 1 patients developed massive effusion within one month after initiating ICI treatment, usually within two weeks. The first time cytological examinations of thoracentesis after treatment revealed positive for malignancy in all these patients. Their development of effusion could be interpreted as “pseudoprogression”, because the cytological examinations turned negative in the serial thoracentesis afterwards. Fulminant effusion development was resolved within two months after ICI use.

Most researchers reported survival benefits of pseudoprogression markedly better than that of typical progression. In our study, type 1 patients had longer PFS and OS than those of type 3 and type 2 patients. Some studies reported that the malignant pleural effusion present before anti-PD-1 treatment is associated with shorter PFS and OS. In our study, if pseudoprogression occurred as type 1 pleural effusion, long-term survival could be achieved. Therefore, ICI should still be considered in patients with malignant pleural effusion.

Type 1 pleural effusion developed one month after ICI treatment had begun. The time from treatment to first thoracentesis was as long as 25 months (case no.8). It is not surprising that the occurrence of irAEs was delayed, since Nigro et al. reported earlier that late-irAEs (after 12 months) are common (incidence 30.3%) in long responders to ICIs. The cytology of pleural effusion was never documented positive before or after ICI use so this type was not categorized as pseudoprogression. Thoracentesis was usually infrequent. No more drainage was recorded after the first two months of therapy. That case shared a similar clinical presentation with our type 1 patients and may be categorized as “type 1” pleural effusion.

Three type 3 patients had initial pleural effusion CD4/CD8 ratios > 1.93. Patient no.11 and 12 showed partial responses at the primary lesion, but development of new lesions was noted during follow up. No further treatment was given after disease progression due to poor performance status. This challenged the interpretation of OS. Patient no.17 developed pleural effusion 19 months after starting durvalumab medication, and CD4/CD8 and B cell ratios then increased, while cytological results were positive. Nevertheless, the PFS of this patient went up to 18.4 months. Infrequent thoracenteses was performed and there’s no disease progression to the other organs beyond the pleura. Longer follow ups are desirable as the clinical presentation was different from other type 3 patients.

Infiltration of inflammatory cells with CD4+ predominant may contribute to elevated CD4/CD8 ratio in the pleural effusion. Scherpereel et al. evaluated T cell populations in patients with pleural effusion. Their blood CD4/CD8 ratios were 1.6. In healthy subjects, the ratio in pleural fluid is 0.59, compared with higher ratios of 3.8 in patients with pleural metastasis. Aguilar et al. found CD4/CD8 ratios were similarly higher in malignant pleural effusion than in the peripheral blood (i.e., 3.6 vs 1.4). Nieto et al. reported that in patients after diagnosing malignant pleural effusion, their lymphocytes count in the pleural effusion is positively correlated with survival. CXCL10 helps attract lymphocytes in malignant effusion. Accordingly, in patients with malignant pleural effusion, CD4/CD8 ratio of which is higher than the peripheral blood. This may be a defensive mechanism against cancer, and ICI likely reinforces the mechanism.

Regarding irAEs, cytokines or chemokines in response to ICIs have been studied. Khan et al. reported irAEs patients have initially low levels of CXCL9, 10, 11 and 19, but levels of CXCL 9, and 10 remarkably increase after treatment compared with those patients without irAEs. Lim et al. found elevations of 11 cytokines in patients with severe irAEs, and even introduced a cytokine toxicity score. IL-17 and IL-6 levels were reported as biomarkers in predicting irAEs. In our study, we found IL-8 levels in patients with pleural effusion CD4/CD8 ratio < 1.93 were higher than those with ratio > 1.93. IL-8, a chemokine produced by cancer cells, could play a role in cancer microenvironment. Higher IL-8 levels are correlated with poor prognosis. Only one patient from the type 1 group had a higher level of IL-17. We can also examine several other cytokines including IL-1, IL-2, IL-4, IL-6, IL-12p70, INF-γ, and TNF-α. However, the levels of these cytokines are either under detection limit or demonstrate no significant difference among the three types of patients.

There were several limitations of our study. First, its sample size was small, and was conducted retrospectively in a single medical center. Second, not all patients had their CD4/CD8 ratios determined at the initial thoracentesis. Also, their CD4/CD8 ratios were not determined before ICI treatment nor their ratio in the peripheral blood. Third, 11 of 17 patients received both chemotherapy and ICI, presenting a confounder on response evaluation. However, no patient was lost during follow up and all required clinical information was collected. We are the first to report two distinct types of pleural effusions after ICI use. These two types of patients both had relatively good prognosis. Our study is also the first to use the CD4/CD8 ratio in pleural effusion to predict patient survival after ICI use.

In conclusion, beside pleural effusion due to disease progression (type 3), two distinct effusion types were identified after ICI use: type 1, rapid (develop < 1 month) and massive and type 2, slow (develop > 1 month) and relative indolent. Both types showed better overall and progression free survival than type 3. Type 1 could be interpreted as pseudoprogression of malignant pleural effusion. CD4/CD8 ratio > 1.93 in pleural effusion after ICI use is a good predicting factor in PFS. In most patients of types 1 and 2, their CD4/CD8 ratios > 1.93 in pleural effusion. In those patients presented with typical type 1 or type 2 pleural effusion but with CD4/CD8 ratios < 1.93, serial follow up is recommended because elevating ratio may indicate a good response to ICI.
Declarations

Acknowledgments
None

Author contributions

Po-Hsin Lee: Methodology, Methodology, Software, Formal analysis, Data Curation, Writing - Original Draft, Visualization
Tsung-Ying Yang: Investigation, Resources
Kun-Chieh Chen: Investigation, Resources
Yen-Hsiang Huang: Formal analysis, Resources
Jeng-Sen Tseng: Formal analysis, Resources, Writing - Original Draft
Kuo-Hsuan Hsu: Investigation, Resources
Yu-Chen Wu: Resources, Data Curation
Ko-Jiunn Liu: Conceptualization, Methodology, Validation, Resources, Data Curation, Writing - Review & Editing, Supervision
Gee-Chen Chang: Conceptualization, Methodology, Validation, Resources, Writing - Review & Editing, Supervision, Project administration

Additional Information (including a Competing Interests Statement)

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

1. Ferrara, R., Caramella, C., Besse, B. & Champiat, S. Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?. Journal of Thoracic Oncology. 14, 328–331 (2019).
2. Kolla, B. C. & Patel, M. R. Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy—a report of two cases. Journal for immunotherapy of cancer. 4, 80 (2016).
3. Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine. 378, 158–168 (2018).
4. Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. New England Journal of Medicine. 375, 1749–1755 (2016).
5. Anastasia, S. et al. Pericardial effusion under nivolumab: case-reports and review of the literature. Journal for immunotherapy of cancer. 7, 266 (2019).
6. Semb, K. A., Aamdal, S. & Oian, P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. Journal of Clinical Oncology. 16, 3426–3432 (1998).
7. Hsu, K. H. et al. Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan. Plos one10(2015).
8. Garon, E. B. et al. Pembrolizumab for the treatment of non–small-cell lung cancer. New England Journal of Medicine. 372, 2018–2028 (2015).
9. Nieto, J. C. et al. Migrated t lymphocytes into malignant pleural effusions: an indicator of good prognosis in lung adenocarcinoma patients. Scientific reports. 9, 1–11 (2019).
10. Gettinger, S. N. et al. Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer. Journal of clinical oncology 33, 2004 (2015).
11. Nishino, M. et al. Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions. Clin. Cancer Res. 23, 4671–4679 (2017).
12. Tazdait, M. et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. European Journal of Cancer. 88, 38–47 (2018).
13. Fujimoto, D. et al. Pseudoprogression in Previously Treated Patients with Non–Small Cell Lung Cancer Who Received Nivolumab Monotherapy. Journal of Thoracic Oncology. 14, 468–474 (2019).
14. Shibaki, R. et al. Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer. Thoracic cancer. 10, 815–822 (2019).
15. Nigro, O. et al. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. European Journal of Cancer. 134, 19–28 (2020).
16. Scherpereel, A. et al. Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid. BMC cancer. 13, 324 (2013).
17. Aguiar, L. M. Z. et al. Malignant and tuberculous pleural effusions: immunophenotypic cellular characterization. Clinics 63, 637–644(2008).
18. Khan, S. et al. Immune dysregulation in cancer patients developing immune-related adverse events. *British journal of cancer.* **120**, 63–68 (2019).

19. Lim, S. Y. et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1–based immunotherapy. *Clin. Cancer Res.* **25**, 1557–1563 (2019).

20. Anderson, R., Theron, A. J. & Rapoport, B. L. Immunopathogenesis of immune checkpoint inhibitor-related adverse events: roles of the intestinal microbiome and Th17 cells. *Frontiers in immunology.* **10**, 2254 (2019).

21. Ke, W., Zhang, L. & Dai, Y. The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs). *Thoracic Cancer.* **11**, 835–839 (2020).

22. Alfaro, C. et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). *Clin. Cancer Res.* **22**, 3924–3936 (2016).